Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Smolen, J. S. et al. Rheumatoid arthritis. Nat. Rev. Dis. Primers 4, 18001 (2018).
2. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2019-216655 (2020).
3. Lund Hetland, M. et al. A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy and safety results of the NORD-STAR Trial [abstract L09]. Arthritis Rheumatol. 71 (Suppl. 10), 5237–5240 (2019).
4. Croft, A. P. et al. Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570, 246–251 (2019).
5. Aletaha, D. & Smolen, J. S. Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat. Rev. Rheumatol. 15, 633–634 (2019).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献